Ipsen has announced the presentation of new study data on Dysport (abobotulinumtoxinA) in stroke and other neurological disorders. The data will be presented at the TOXINS 2026 conference in Madrid, Spain.
The company will present interim analysis from its ongoing EPITOME study. The study is evaluating adults from ages 18-85 following their first stroke in order to develop a clearer picture of the frequency of post-stroke spasticity (PSS), as well as to improve early identification of PSS. A Post-stroke Spasticity Monitoring Questionnaire is being used by the study to assist doctors in identifying early signs of PSS.
PSS, a condition that causes muscle stiffness and pain, frequently goes undiagnosed after a stroke: this can cause issues for both treatment and recovery. Remote monitoring of stroke patients could help healthcare providers to intervene more rapidly if PSS occurs.
The interim analysis of the EPITOME study showed that 45.7% of stroke survivors with paresis developed spasticity within one year of their stroke, compared to a previously-recorded 39.5%. An increase in rapidly identified PSS could be crucial in light of the fact that, according to real-world data, less than 1% of stroke survivors receive botulinum toxin type A (BoNT-A) treatment for PSS.
Dysport is an injectable form of BoNT-A. It helps to reduce muscle contractions by blocking the transmission of nerve impulses.
Sandra Silvestri, executive vice president and chief medical officer at Ipsen, said: “This breadth of data [underscores] our mission to bring solutions and address care gaps for people living with a broad range of neurological conditions. The EPITOME study is one example of this, focused on providing a standardised and best-practice follow-up to ensure people living after a stroke receive the care they deserve.”
Ipsen is a global biopharmaceutical company specialising in oncology, rare disease and neuroscience.
